Dyax

 

Advancing Novel Biotherapeutics Since 1995®

Investor Relations

Dyax is a fully integrated biopharmaceutical company focused on developing and commercializing products for unmet medical needs. We currently market a product for the treatment of acute attacks of hereditary angioedema (HAE), a rare genetic disease (to learn more, click here). We also have an investigational drug candidate in development for the prevention of HAE attacks (to learn more, click here).

Both our commercial product and drug candidate in development were identified using Dyax’s proprietary phage display technology. We have broadly licensed this technology and have a portfolio of product candidates being developed by our licensees that we refer to as the Licensing and Funded Research Portfolio (LFRP). This portfolio includes one approved product for which we receive royalties. Additionally, there are multiple product candidates in various stages of clinical development for which we are eligible to receive future milestones and/or royalties (to learn more, click here).

More »Stock Quote

DYAX (Common Stock)
Exchange NASDAQ (US Dollars)
Price $16.54
Change (%) 0.34 (2.10)%
Volume 1,261,800
Data as of Mar 27, 2015 4:00 PM ET
Delayed at least 20 minutes. Provided by eSignal.
Refresh Quote

More »Recent Releases

Date Title
Feb 24, 2015 Dyax Corp. Announces Fourth Quarter and Full Year 2014 Financial Results
Feb 18, 2015 Dyax Corp. to Participate in Upcoming Investor Conferences
Feb 10, 2015 Dyax Corp. to Host Fourth Quarter and Year End 2014 Earnings Call and Webcast
Feb 4, 2015 Dyax Corp. to Participate in the Leerink Partners 2015 Global Healthcare Conference

More »Calendar of Events

Details on upcoming events are not yet available.

More » Event Archives

Mar 2, 2015 Cowen and Company 35th Annual Health Care Conference
Feb 25, 2015 RBC Healthcare Conference
Feb 24, 2015 Dyax Corp. 4Q 2014 Earnings Call
Feb 11, 2015 Leerink Global Healthcare Conference

Featured Financial Reports

Filing Date Title Type Size
Feb 27, 2015 10-K View HTML View PDF 1.2 MB Add to Briefcase
Dec 31, 2013 2013 Annual Report PDF  508.9 KB Add to Briefcase
Add to Briefcase = add file to Briefcase
 

You are now leaving Dyax.com.

The web site you are about to visit is . It is neither owned nor controlled by Dyax Corp. Dyax is not responsible for the content, products or services on this site.

Do you wish to continue?